Astellas Pharma China, Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 1994-10-14

Employees: -

Market Cap: -

Website: https://www.astellas.com.cn

Clinical Trials

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Phase 3

Active, not recruiting

Conditions: Metastatic Hormone Sensitive Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Placebo
Drug: Androgen deprivation therapy (ADT)

First Posted Date: 2019-09-03

Last Posted Date: 2024-12-19

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 180

Registration Number: NCT04076059

Locations: 🇨🇳
Site CN86009, Changsha, China
🇨🇳
Site CN86025, Fuzhou, China
🇨🇳
Site CN86010, Shanghai, China

and more 27 locations

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Phase 3

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Peficitinib
Drug: Disease-modifying antirheumatic drugs (DMARDs)
Drug: Plaebo

First Posted Date: 2018-09-06

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 385

Registration Number: NCT03660059

Locations: 🇨🇳
Site CN00061, Changchun, China
🇨🇳
Site CN00072, Guangzhou, China
🇰🇷
Site KR00035, Seoul, Korea, Republic of

and more 40 locations

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: Tacrolimus immediate-release formulation
Drug: Tacrolimus prolonged-release formulation
Drug: Induction therapy
Drug: Mycophenolic acid drugs
Drug: Corticosteroids

First Posted Date: 2018-08-23

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 284

Registration Number: NCT03644485

Locations: 🇨🇳
Site CN08619, Beijing, China
🇨🇳
Site CN08609, Changsha, China
🇨🇳
Site CN08603, Tianjin, China

and more 11 locations

Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

Phase 4

Completed

Conditions: Renal Transplant Recipients

Interventions: Drug: Tacrolimus sustained-release capsule

First Posted Date: 2016-03-11

Last Posted Date: 2024-11-08

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 105

Registration Number: NCT02706678

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Completed

Conditions: Invasive Fungal Infections

Interventions: Drug: Micafungin

First Posted Date: 2016-02-10

Last Posted Date: 2016-02-10

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 2555

Registration Number: NCT02678598

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

Phase 4

Terminated

Conditions: Invasive Aspergillosis

Interventions: Drug: Micafungin

First Posted Date: 2016-01-06

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 43

Registration Number: NCT02646774

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

Phase 4

Terminated

Conditions: Candidiasis
Aspergillosis

Interventions: Drug: Micafungin

First Posted Date: 2016-01-06

Last Posted Date: 2024-11-07

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 105

Registration Number: NCT02646800

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

Phase 3

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Cyclophosphamide injections
Drug: Tacrolimus capsules
Drug: Prednisone

First Posted Date: 2015-05-29

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 314

Registration Number: NCT02457221

Locations: 🇨🇳
Site CN00005, Dalian, Liaoning, China
🇨🇳
Site CN00045, Liuzhou, Guangxi, China
🇨🇳
Site CN00025, Nanjing, Jiangsu, China

and more 32 locations

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

Completed

Conditions: Kidney Transplant Recipients

Interventions: Drug: ATF-Fresenius S

First Posted Date: 2015-03-18

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 950

Registration Number: NCT02392312

Locations: 🇨🇳
Site: CN00017, Jinan, China
🇨🇳
Site: CN00023, Guangzhou, China
🇨🇳
Site: CN00033, Yantai, China

and more 22 locations

A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

Phase 4

Terminated

Conditions: Kidney Transplant Recipients

Interventions: Drug: Advagraf
Drug: Prograf

First Posted Date: 2014-10-20

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma China, Inc.

Target Recruit Count: 17

Registration Number: NCT02268201

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy